A new compound reversed many of the major symptoms of fragile X syndrome in mice, scientists from Hoffmann-LaRoche and Massachusetts Institute of Technology reported in the April 12 Neuron. Although the drug, called CTEP, is not being developed for humans, the findings still have significance for humans with fragile X syndrome, which has several behavioral and cognitive symptoms that overlap with those seen in autism. "The most important implications of our study are that many aspects of fragile X syndrome are not caused by an irreversible disruption of brain development and that correction of the altered glutamate signaling can provide widespread therapeutic benefit," the lead scientist wrote in an accompanying press release.Even though fragile X syndrome and autism share symptoms, these symptoms do not arise from the same brain abnormalities, other researchers reported a few months ago. The results of these studies may also have clinical implications, the researchers suggested. More information about this study can be found in Psychiatric News. (Image: ZouZou/Shutterstock.com)
